These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Fundamental and clinical studies on cefotaxime in the field of obstetrics and gynecology (author's transl)].
    Author: Motomura R, Mori H, Teramoto C, Nishimura Y, Souda Y, Yamabe T.
    Journal: Jpn J Antibiot; 1981 Apr; 34(4):521-31. PubMed ID: 6270401.
    Abstract:
    UNLABELLED: Fundamental and clinical studies were made on cefotaxime (CTX), a new cephalosporin antibiotic. The following results were obtained: 1. Antibacterial activity: At a concentration of 3.13 mcg/ml, CTX inhibited the growth of 90.2% of 92 strains of Gram-negative rods and 80.0% of 15 strains of Gram-positive cocci. 2. Concentrations of CTX in body fluids and genital organs after 2 g i.v.: (1) CTX level in pus reached the peak (5.6mcg/ml) at 2 hours after administration. (2) Mean CTX levels in the pelvic space exudate reached the peak (28.0 mcg/ml) at 2 hours after administration. (3) CTX levels in the uterine appendages and uterus reached the peak (8.9 and 4.5 mcg/g, respectively) at 100 to 280 minutes after administration. 3. CLINICAL RESULTS: CTX was excellent in 7 of 13 cases and good in the remaining 6 cases. The response rate to CTX was 100%. 4. The bacteriological effect: The bacteriological effect of CTX was also 100%. Bacteria were eradicated in 7 of the 10 cases where organisms were demonstrated before CTX treatment. Partial reduction bacteria was observed in the remaining 3 cases. 5. No side effect attributable to CTX was observed.
    [Abstract] [Full Text] [Related] [New Search]